2 Information about bulevirtide

Marketing authorisation indication

2.1 Bulevirtide (Hepcludex, Gilead) has a conditional marketing authorisation 'for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV RNA positive adult patients with compensated liver disease'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for bulevirtide.


2.3 The list price of 2 milligram vials of bulevirtide is £6,500 for 30 vials (excluding VAT; BNF online accessed May 2023).

2.4 The company has a commercial arrangement. This makes bulevirtide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)